The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for pati
BackgroundOverall risks of hepatotoxicity with immune checkpoint inhibitors (ICIs) have yet to be compared in primary liver cancers to other solid tumors. MethodsWe reviewed data from the PubMed, Emba
Objective: To explore the use and safety of penpulimab in real world. Methods: Totally 13 inpatients using penpulimab were observed from April to December 2022 in a cancer hospital. The data of patien